Cargando…
Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid agonist therapy (OAT) is scarce. This study examined ADHD symptoms using the AD...
Autores principales: | Vold, Jørn Henrik, Halmøy, Anne, Chalabianloo, Fatemeh, Pierron, Marianne Cook, Løberg, Else-Marie, Johansson, Kjell Arne, Fadnes, Lars Thore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308780/ https://www.ncbi.nlm.nih.gov/pubmed/37386438 http://dx.doi.org/10.1186/s12888-023-04980-w |
Ejemplares similares
-
Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020
por: Vold, Jørn Henrik, et al.
Publicado: (2021) -
Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
Prevalence and correlates of suicide attempts in high-risk populations: a cross-sectional study among patients receiving opioid agonist therapy in Norway
por: Vold, Jørn Henrik, et al.
Publicado: (2022)